Table 3 Adverse events occurred in at least 5% of subjects in either group a
Event | n-CEA (n = 20) | DCEAS (n = 23) |
|---|---|---|
Fatigue | 8 (40.0) | 11 (47.8) |
Needling-induced discomfort | 6 (30.0) | 7 (30.4) |
Headache | 6 (30.0) | 4 (17.4) |
Dizziness | 1 (5.0) | 4 (17.4) |
Nausea | 2 (10.0) | 1 (4.3) |
Vomiting | 0 | 2 (8.7) |
Depression deterioration | 2 (10.0) | 3 (13.0) |
Movement disorder | 3 (15.0) | 5 (21.7) |
Sweating | 1 (5.0) | 1 (4.3) |
Palpitation | 1 (5.0) | 5 (21.7) |
Insomnia | 3 (15.0) | 6 (26.1) |
Hypersomnia | 2 (10.0) | 8 (34.8) |